Fate Therapeutics (NASDAQ: FATE) reviewed 10-14-2020
Market Cap: $4.1 Billion (USD) Share Price: $46.96 (USD)
Shares outstanding: 86,802,162
Cash & cash equivalents: $433 Million (USD) at 30 Jun 2020
Debt: None stated on the balance sheet
Insiders: 2% Institutional: 221 holders own 96% of the float
Website: fatetherapeutics.com
Investor Presentations: https://ir.fatetherapeutics.com/
CEO: Scott Wolchko HQs: San Diego, CA USA
The company is developing cellular immunotherapy technologies for cancer and immune disorders
The company has about 14 iPSC-derived cell products in the pipeline in various Pre-clinical stages
Revenues improved in 2019 to $10.68M (USD) from $4.74M (USD) in 2018
The company has been operating at a loss for consecutive years
Loss of $0.79 (USD) per share in the six months to 30 Jun 2020. Lost $0.66 (USD) per share in the same period of 2019
Has collaborations with Janssen Biotech and Ono Pharmaceutical Co., the Masonic Cancer Center in Minneapolis, Minnesota, the Memorial Sloan-Kettering Cancer Center, and Oslo University
Bottom Line:
- Uses pluripotent stem cell line to discover immunotherapies for cancer and immune disorders, which if their phase 2 clinical trial is successful, we believe the company is a buy-out candidate